24/7 Market News Snapshot 04 February, 2025 – Quoin Pharmaceuticals, Ltd. American Depositary Shares (NASDAQ:QNRX)

February 4, 2025

DENVER, Colo., 04 February, 2025 (247marketnews.com) – (NASDAQ:QNRX) are discussed in this article.
Quoin Pharmaceuticals, Ltd. (QNRX) has recently experienced a significant surge in its stock price, opening at $0.33 and currently trading at approximately $0.426, marking an increase of 44.41%. This upward movement is accompanied by a robust trading volume of 9.26 million shares, indicating heightened investor interest and confidence in the company’s potential. Following a close at $0.295, this rebound suggests a possible breakout from previous resistance levels, potentially driven by favorable market sentiment or key developments regarding the company’s therapeutic pipeline.

In conjunction with this positive market performance, Quoin Pharmaceuticals is also launching the “NETHERTON NOW” campaign to raise awareness about Netherton Syndrome, a rare genetic disorder that severely impacts skin health. This initiative is particularly timely as the company approaches the first regulatory approval for its investigational product, QRX003, designed to treat this debilitating condition. Netherton Syndrome, often misdiagnosed and associated with high mortality rates among infants, necessitates increased awareness and effective treatment options.

“Our commitment to the Netherton community is unwavering,” said Quoin CEO Dr. Michael Myers, emphasizing the company’s dedication to delivering a safe and effective solution for those affected. The NETHERTON NOW campaign includes the launch of an interactive website offering educational resources and research updates, aimed at unifying the community in advocacy efforts.

Quoin is progressing with various clinical studies to evaluate the safety and efficacy of QRX003, with recent data showcasing promising results and significant patient improvements. The company is preparing for a comprehensive ‘whole body’ clinical study, which has received clearance from regulatory authorities, further underscoring QRX003’s potential as a transformative treatment. Quoin Pharmaceuticals remains resolute in its mission to elevate the voices of patients facing Netherton Syndrome, ensuring their challenges are recognized and addressed.

Related news for (QNRX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.